Leukemia Clinical Trials in Philadelphia

Showing 441-460 of 1,308 trials

Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET

NCT05420636

This is a non-randomized single-arm, two cohorts, phase II study of iadademstat in combination with weekly paclitaxel in patients with relapse/refractory SCLC or extrapulmonary G3 Neuroendocrine Carcinomas. A total of 42 patients with SCLC (21 patients) and G3 NEC (21 patients) will be enrolled (including those enrolled in the safety lead-in portion).

Small-cell Lung CancerNeuroendocrine Carcinoma

Fox Chase Cancer Center20 participantsStarted Dec 2022

Buffalo, New York, United States • Philadelphia, Pennsylvania, United States • Salt Lake City, Utah, United States

RECRUITINGPhase 1/2< 1 mile

Phase IB/II of CPX-351 for Relapse Prevention in AML

NCT04990102

This is a phase IB/II study with a 3+3 dose de-escalation study design. Patients will continue maintenance treatment with CPX-351 for 6 cycles on D1 and D3, as long as patient remains in CR. The dose de-escalation will be one dose given on D1 only, every 28 days pending toxicity. The maximum tolerated dose will be used for the phase II expansion portion of the study.

Acute Myeloid Leukemia (AML) in Remission

Georgetown University24 participantsStarted May 2023

Washington D.C., District of Columbia, United States • Hackensack, New Jersey, United States • Philadelphia, Pennsylvania, United States

RECRUITINGNA< 1 mile

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

NCT05237258

This research study is evaluating whether primary palliative care is an alternative strategy to specialty palliative care for improving quality of life, symptoms, mood, coping, and end of life outcomes in patients with acute myeloid leukemia (AML).

Relapsed Adult AMLPrimary Refractory Acute Myeloid LeukemiaHigh Risk Acute Myeloid Leukemia

Massachusetts General Hospital2,300 participantsStarted Jun 2022

Birmingham, Alabama, United States • Stanford, California, United States • Denver, Colorado, United States +17 more locations

Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET

Phase IB/II of CPX-351 for Relapse Prevention in AML

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

Leukemia Trials in Other Cities

Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

Prognostication of Recovery in Early Disorders of Consciousness Study

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

Using Urine Samples to Identify Lung Cancer

Study of DKN-01 and Gemcitabine/Cisplatin in Patients With Carcinoma to Primary to the Intra- or Extra-Hepatic Biliary System or Gallbladder

A Long-term Follow-up Study of Patients Who Received VOR33

Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy

AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia

MGC018 With or Without MGA012 in Advanced Solid Tumors

A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery

Open-Label Surufatinib in European Patients With NET

A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced/Metastatic HER2 Expressing Solid Tumors

A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).

Transorb™ Self-Gripping Resorbable Mesh in High-risk Subjects Undergoing Open Repair of Ventral Hernia

CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

Other Conditions in Philadelphia